← Back to Search

Active Surveillance for Non-Small Cell Lung Cancer (ACTION-Lung Trial)

N/A
Waitlist Available
Research Sponsored by University of Vermont Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two years
Awards & highlights

ACTION-Lung Trial Summary

This study is evaluating whether active surveillance is a good option for lung cancer patients.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Lung Carcinoid Tumor

ACTION-Lung Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Objective: Freedom-from radiation rate for patients on active surveillance
Secondary outcome measures
Secondary Objective: umber of participants on active surveillance with increased anxiety, depression, and uncertainty
Other outcome measures
Correlative Science Objective

Side effects data

From 2020 Phase 2 trial • 227 Patients • NCT02799745
9%
Hypertension
5%
Upper respiratory tract infection
4%
Fatigue
4%
Arthralgia
4%
Back pain
4%
Dysuria
4%
Pollakiuria
4%
Erectile dysfunction
3%
Gynaecomastia
2%
Weight decreased
1%
Angina pectoris
1%
Atrial fibrillation
1%
Cardiac tamponade
1%
Coronary artery perforation
1%
Abdominal pain
1%
Chronic sinusitis
1%
Basal cell carcinoma
1%
Bladder transitional cell carcinoma
1%
Malignant pleural effusion
1%
Haemorrhagic stroke
1%
Movement disorder
1%
Presyncope
1%
Pulmonary mass
1%
Physical disability
1%
Diarrhoea
1%
Nausea
1%
Libido decreased
1%
Breast tenderness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Active Surveillance
Enzalutamide

ACTION-Lung Trial Design

1Treatment groups
Experimental Treatment
Group I: Active SurveillanceExperimental Treatment1 Intervention
Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.

Find a Location

Who is running the clinical trial?

University of Vermont Medical CenterLead Sponsor
41 Previous Clinical Trials
25,799 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Active Surveillance in Early Lung Cancer
Christopher Anker 2018. "Active Surveillance in Early Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03923777.
~4 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top